Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Last trade$7.22
Day change-$0.10 (-1.37%)
Day range$6.82 – $7.51
Volume512,051
Market cap$484M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$484.02M
Price / earnings
—
Price / book
3.27×
Price / sales
3.14×
EV / sales
2.52×
EV / EBITDA
-2.28×
Profitability
Earnings per share
-$2.65
Return on assets
-37.6%
Return on equity
-118.36%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.74×
Quick ratio
4.74×
Cash ratio
1.42×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$154.8M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RGNX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$9.16M
$108.02M
$6.39M
$30.34M
$29.73M
$21.36M
$89.01M
$21.21M
Cost of revenue
$1.14M
$1.04M
$11.07M
$5.93M
$5.73M
$5.21M
$3.44M
$6.32M
Gross profit
$8.02M
$106.98M
-$4.68M
$24.41M
$24.01M
$16.15M
$85.58M
$14.9M
Selling, general and administrative
$20.58M
$21.62M
$21.31M
$22.38M
$20.25M
$19.88M
$20.35M
$20.05M
Research and development
$61.01M
$56.09M
$57.34M
$59.61M
$56.1M
$59.5M
$53.09M
$50.38M
Total operating expenses
$43.56M
$77.71M
$78.68M
$82.05M
$76.42M
$79.43M
$73.45M
$66.26M
Operating income
-$35.53M
$29.26M
-$83.36M
-$57.64M
-$52.41M
-$63.28M
$12.13M
-$51.37M
Interest expense
-$7.47M
-$7.79M
-$8.71M
-$12.28M
-$13.17M
-$10.99M
-$8.57M
-$9.42M
Income before taxes
-$40.74M
$22.71M
-$90.05M
-$67.15M
-$61.94M
-$70.87M
$6.08M
-$51.19M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$40.74M
$22.71M
-$90.05M
-$67.15M
-$61.94M
-$70.87M
$6.08M
-$51.19M
Net income attributable to common shareholders
-$40.74M
$22.71M
-$90.05M
-$67.15M
-$61.94M
-$70.87M
$6.08M
-$51.19M
EBITDA
-$70.05M
$33.02M
-$79.51M
-$53.77M
-$48.53M
-$59.37M
$16.08M
-$47.35M
Basic earnings per share
-$0.62
$0.43
-$1.72
-$1.30
-$1.20
-$1.38
$0.12
-$1.01
Diluted earnings per share
-$0.62
$0.43
-$1.72
-$1.30
-$1.20
-$1.38
$0.12
-$1.01
Recent news
Company coverage with links to the original publishers.
Regenxbio (RGNX) has a mean analyst price target of $24, suggesting 214.6% upside potential from its current $7.63 price. The stock has received a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions over the past 30 days. However, the article cautions that price targets alone should not be the sole basis for investment decisions, as analysts often set overly optimistic targets due to business incentives.
Kuehn Law is investigating whether officers and directors of Regenxbio, Inc. breached fiduciary duties by providing false or misleading information about the efficacy and safety of RGX-111, a gene therapy for Hurler Syndrome. The firm is seeking shareholders who purchased stock prior to February 9, 2022.
A comprehensive pipeline analysis reveals over 50 companies developing 55+ drugs for diabetic retinopathy treatment. Key developments include Kodiak Sciences' Tarcocimab tedromer (Phase III anti-VEGF therapy), Vantage Biosciences' VX-01 (Phase II oral treatment), and Therini Bio's THN391 (Phase I fibrin-targeting therapy). The report covers therapeutic assessments across various development stages, routes of administration, and molecule types, highlighting emerging opportunities in retinal disease treatment.
DelveInsight's 2026 report reveals a robust AMD clinical trial pipeline with 90+ active players developing 100+ pipeline drugs across various clinical stages. The report highlights promising therapies including elamipretide, 4D-150, MK-8748, and SAR402663, with approximately 15+ drugs in late-stage development. Recent advances include Merck's Phase IIb/III trial initiation for MK-8748, 4D Molecular Therapeutics' Phase III enrollment completion for 4D-150, and FDA fast-track designation for SAR402663.
REGENXBIO Inc. (NASDAQ: RGNX) faces a class action lawsuit for securities violations. The company allegedly made false and misleading statements about the safety and efficacy of its RGX-111 product candidate while concealing adverse information from investors. The FDA placed a clinical hold on RGX-111 after a clinical trial participant developed a tumor. Shareholders who purchased shares between February 9, 2022 and January 27, 2026 are encouraged to contact DJS Law Group regarding potential recovery.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.